Effect of the oral endothelin antagonist bosentan on the clinical, exercise, and haemodynamic status of patients with pulmonary arterial hypertension related to congenital heart disease

Heart

Volumn 91, Issue 11, 2005, Pages 1447-1452

  Apostolopoulou, Sotiria C ^a   Manginas, A ^a   Cokkinos, D V ^a   Rammos, S ^a  

^a ONASSIS CARDIAC SURGERY CENTER   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

BOSENTAN; ENDOTHELIN RECEPTOR ANTAGONIST;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONGENITAL HEART DISEASE; DISEASE ASSOCIATION; DIZZINESS; DRUG SAFETY; DYSPNEA; EISENMENGER COMPLEX; EXERCISE; EXERCISE TEST; FEMALE; FLUSHING; HEART ARRHYTHMIA; HUMAN; LIVER DYSFUNCTION; LUNG ARTERY PRESSURE; LUNG BLOOD FLOW; LUNG HEMODYNAMICS; LUNG VASCULAR RESISTANCE; MALE; NOSE CONGESTION; OXYGEN CONSUMPTION; OXYGEN SATURATION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SIDE EFFECT; TREADMILL EXERCISE; WALKING; WORLD HEALTH ORGANIZATION;

ADMINISTRATION, ORAL; ADULT; ANTIHYPERTENSIVE AGENTS; CHRONIC DISEASE; EXERCISE; EXERCISE TOLERANCE; FEMALE; HEART DEFECTS, CONGENITAL; HEMODYNAMIC PROCESSES; HUMANS; HYPERTENSION, PULMONARY; MALE; OXIMETRY; SULFONAMIDES; TREATMENT OUTCOME;

EID: 27444437374     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2004.051961     Document Type: Article

References (28)

1. Rubin U. Primary pulmonary hypertension. N Engl J Med 1997;336:111-7.
2. MacGregor AJ, Canavan R, Knight C, et al. Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. Rheumatology (Oxford) 2001;40:453-9.
3. Ivy D. Diagnosis and treatment of severe pediatric pulmonary hypertension. Cordiol Rev 2001;9:227-37.
4. Daliento L, Somerville J, Presbitero P, et al. Eisenmenger syndrome: factors relating to deterioration and death. Eur Heart J 1998;19:1845-55.
5. Wagenvoort CA, Wagenvoort N. Pathology of the Eisenmenger syndrome and primary pulmonary hypertension. Adv Carrdiol 1974;11:123-30.
6. Wort SJ, Woods M, Warner TD, et al. Endogenously released endothelin-1 from human pulmonary artery smooth muscle promotes cellular proliferation: relevance to pathogenesis of pulmonary hypertension and vascular remodeling. Am J Respir Cell Mol Biol 2001;25:104-10.
7. Dupuis J, Cernacek P, Tardif JC, et al. Reduced pulmonary clearance of endothelin-1 in pulmonary hypertension. Am Heart J 1998;135:614-20.
8. Allen SW, Chatrield BA, Koppenhafer SA, et al. Circulating immunoreactive endothelin-1 in children with pulmonary hypertension: association with acute hypoxic pulmonary vasoreactivity. Am Rev Respir Dis 1993;148:519-22.
9. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001;358:1119-23.
10. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903.
11. Prendergast B, Newby DE, Wilson LE, et al. Early therapeutic experience with the endothelin antagonist BQ-123 in pulmonary hypertension after congenital heart surgery. Heart 1999;82:505-8.
12. Apostolopoulou SC, Rammos S, Kyriakides ZS, et al. Acute endothelin A receptor antagonism improves pulmonary and systemic haemodynamics in patients with pulmonary arterial hypertension that is primary or autoimmune and related to congenital heart disease. Heart 2003;89:1221-6.
13. Barst RJ, Ivy D, Dingemanse J, et al. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clin Pharmacol Ther 2003;73:372-82.
14. Christensen DD, McConnell ME, Book WM, et al. Initial experience with bosentan therapy in patients with the Eisenmenger syndrome. Am J Cardiol 2004;94:261-3.
15. Rich S, ed. Primary pulmonary hypertension: executive summary from the World Symposium on Primary Pulmonary Hypertension, Evian, France, 6-10 September 1998.
16. Guyatt GH, Sullivan MJ, Thompson PJ, et al. The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. Can Med Assoc J 1985;132:919-23.
17. Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc 1982;14:377-81.
18. Bridges ND, Freed MD. Cardiac catheterization. In: Emmanouilides GC, Riemenscneider TA, Allen HD, et al, eds. Moss and Adams heart disease in infants, children, and adolescents. Baltimore: Williams & Wilkins, 1995:310-28.
19. Grossman W. Clinical measurement of vascular resistance and assessment of vasodilator drugs. In: Grossman W, ed. Cardiac catheterization and angiography. Philadelphia: Lea and Febiger, 1991:143-51.
20. Bush A, Busst CM, Knight WB, et al. Preoperative measurement of pulmonary vascular resistance in complete transposition of the great arteries. Br Heart J 1990;63:300-3.
21. Gomez A, Bialostozky D, Zajarias A, et al. Right ventricular ischemia in patients with primary pulmonary hypertension. J Am Coll Cardiol 2001;38:1137-42.
22. Galie N, Hinderliter AL, Torbicki A, et al. Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and Doppler measures in patients with pulmonary arterial hypertension. J Am Coll Cardiol 2003;41:1380-6.
23. Barst RJ, Rich S, Widlitz A, et al. Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot study. Chest 2002;121:1860-8.
24. Stoica SC, McNeil KD, Perreas K, et al. Heart-lung transplantation for Eisenmenger syndrome: early and long-term results. Ann Thorac Surg 2001;72:1887-91.
25. Rosenzweig EB, Kerstein D, Barst RJ. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation 1999;99:1858-65.
26. Sitbon O, Badesch DB, Channick RN, et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest 2003;124:247-54.
27. Chen SJ, Chen YF, Meng QC, et al. Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats. J Appl Physiol 1995;79:2122-31.
28. Burrell KM, Molenaar P, Dawson PJ, et al. Contractile and arrhythmic effects of endothelin receptor agonists in human heart in vitro: blockade with SB 209670. J Pharmacol Exp Ther 2000;292:449-59.